[The role of antibiotic-therapy referral in therapeutic innovation. Apropos of a case of streptococcal endocarditis].
Asseray
N
N
Université de Nantes, UPRES EA 38 26, Thérapeutique clinique et expérimentale des infections, Nantes, 44 000-F, France.
D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002309:Cardiology; D017576:Daptomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000150:complications; D004697:Endocarditis, Bacterial / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D006801:Humans; D033162:Incidental Findings; D033183:Interdisciplinary Communication; D008175:Lung Neoplasms / Q000150:complications / Q000000981:diagnostic imaging; D008495:Medical Oncology; D010138:Pacemaker, Artificial; D010348:Patient Care Team; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications; D015272:Pulmonary Medicine; D011859:Radiography; D012017:Referral and Consultation; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D013290:Streptococcal Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D013298:Streptococcus sanguis / Q000187:drug effects*; D013903:Thoracic Surgery
D000900:Anti-Bacterial Agents; D017576:Daptomycin; D012293:Rifampin